John F. Carey - 29 Jul 2022 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Signature
By: /s/ Stephen Gordon, as attorney-in-fact
Issuer symbol
TMDX
Transactions as of
29 Jul 2022
Net transactions value
-$245,778
Form type
4
Filing time
01 Aug 2022, 20:40:29 UTC
Previous filing
22 Jul 2022
Next filing
02 Sep 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $27,104 +2,041 +265% $13.28* 2,812 29 Jul 2022 Direct F1, F6
transaction TMDX Common Stock Options Exercise $4,329 +1,959 +70% $2.21* 4,771 29 Jul 2022 Direct F1, F6
transaction TMDX Common Stock Sale $160,040 -4,000 -84% $40.01 771 29 Jul 2022 Direct F1, F2, F6
transaction TMDX Common Stock Options Exercise $6,630 +3,000 +389% $2.21* 3,771 01 Aug 2022 Direct F1, F6
transaction TMDX Common Stock Sale $16,008 -400 -11% $40.02 3,371 01 Aug 2022 Direct F1, F3, F6
transaction TMDX Common Stock Sale $91,058 -2,200 -65% $41.39 1,171 01 Aug 2022 Direct F1, F4, F6
transaction TMDX Common Stock Sale $16,736 -400 -34% $41.84 771 01 Aug 2022 Direct F1, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -2,041 -5.5% $0.000000 34,834 29 Jul 2022 Common Stock 2,041 $13.28 Direct F1, F7
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -1,959 -18% $0.000000 8,784 29 Jul 2022 Common Stock 1,959 $2.21 Direct F1, F8
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -3,000 -34% $0.000000 5,784 01 Aug 2022 Common Stock 3,000 $2.21 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $40.00 to $40.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $39.60 to $40.39, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $40.78 to $41.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $41.78 to $41.95, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The amount of securities directly owned by the Reporting Person includes 392 shares of common stock acquired under the TransMedics Group, Inc. 2019 Employee Stock Purchase Plan.
F7 The option vested and will continue to vest at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 22, 2022. As of the date of this report, the option remains subject to vesting with respect to 34,042 shares.
F8 The option is fully vested.